New hope for aggressive thyroid cancer when other treatments fail

This study is testing whether the immunotherapy drug pembrolizumab (Keytruda) can help control advanced anaplastic thyroid cancer, a rare but very aggressive type of thyroid cancer. The trial includes 12 adults with cancer that cannot be surgically removed or has spread, and who have no other curative treatment options. Participants receive pembrolizumab through an IV every three weeks until the cancer progresses, side effects become too severe, or they choose to stop.